Gang Hu, MD
Ophthalmology · Hurst, TXNPI 1275544884
Payments from drug & device makers
Across 857 payments — averaging $2702.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$1.2M
- Alcon Research LLC$366K
- Rxsight Inc$311K
- AbbVie$194K
- Glaukos Corporation$170K
- Alcon$37K
- plus $32K from 20 others
Across 2 payments — averaging $45.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$91
What the payments were for
- Consulting fees$106,47783%
- Speaking & faculty fees$3,6263%
- Travel & lodging$3,3623%
- Food & beverage$13,82011%
- Education$50%
- Gifts$1980%
- Entertainment$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 136 | $1,205,875 |
| Alcon Research LLC | 175 | $366,240 |
| Rxsight Inc | 73 | $311,343 |
| AbbVie(2 entities) | 43 | $193,641 |
| Glaukos Corporation | 118 | $169,717 |
| Alcon | 193 | $37,453 |
| Sun Pharmaceutical Industries Inc. | 18 | $17,179 |
| Ivantis, Inc | 6 | $5,109 |
| Carl Zeiss Meditec, Inc. | 13 | $3,885 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $2,229 |
| Carl Zeiss Meditec USA, Inc. | 10 | $723 |
| Bausch & Lomb Americas Inc. | 14 | $662 |
| Sight Sciences, Inc. | 20 | $417 |
| Biotissue Holdings Inc. | 6 | $306 |
| Ocular Therapeutix, Inc. | 3 | $224 |
| Aerie Pharmaceuticals, Inc. | 4 | $185 |
| Novartis | 8 | $158 |
| Optos, Inc. | 2 | $149 |
| Oyster Point Pharma, Inc. | 1 | $119 |
| Shire North American Group Inc | 2 | $38 |
| Dompe US, Inc. | 2 | $33 |
| Eyevance Pharmaceuticals LLC | 2 | $25 |
| Amgen | 1 | $23 |
| Eyepoint US, Inc. | 1 | $19 |
| NEW World Medical,inc. | 1 | $16 |
| Lensar, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$45,708
- RXSIGHT INJECTOR CARTRIDGE$45,708
- RXSIGHT INJECTOR HANDPIECE$45,708
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$45,708
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$45,292
- Clareon$11,590
- Centurion$9,100
- iDose$8,730
- Systane$7,000
- LenSx$7,000
- ILUX$7,000
- AcrySof$6,370
- AcrySof IQ PanOptix UV IOL$4,430
- VisuMax$3,683
- AcrySof IQ VIVITY$3,500
- LOTEMAX SM$2,100
- Tecnis Symfony IOL$1,932
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$1,500
- iStent SUPRA Suprachoroidal Micro-Bypass Stent$1,500
- CE-marked KXLA system$1,400
How this compares
$2,315,776 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 991 | $346,417 |
| Prednisolone Acetate | 2,289 | $160,074 |
| MoxifloxacinMoxifloxacin Hcl | 2,668 | $68,938 |
| Bromfenac Sodium | 304 | $53,612 |
| Famciclovir | 40 | $4,733 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $4,077 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $3,795 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $1,964 |
| Latanoprost | 209 | $1,632 |
| Tobramycin | 93 | $453 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 65 | $314 |
| Timolol Maleate | 39 | $187 |
| Pregabalin | 54 | $156 |
| Dorzolamide Hcl | 11 | $87 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $2,229 | $346,417991 claims |
| AbbVieCombigan | $193,641 | $4,07719 claims |
| AlconSimbrinza | $37,453 | $3,79516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Hurst
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.